Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $12 from $15 and keeps an Outperform rating on the shares following quarterly results. The firm says key milestones remain on track; most immediately dose-escalation results from the combination of ORIC-944 with apa/darolutamide.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC: